Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$197.55 USD

197.55
4,713,450

+1.18 (0.60%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $197.40 -0.15 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Pfizer's Xeljanz Combo Comparable to AbbVie's Humira

Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.

    Gilead (GILD) Announces Data on Combination Therapy for HIV

    Gilead Sciences, Inc. (GILD) recently announced positive data from a phase II study on HIV cocktail therapy.

      Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints

      Gilead Sciences' (GILD) fourth quarter results beat on both earnings and sales but the guidance for 2017 was quite disappointing.

        The Zacks Analyst Blog Highlights: Apple, Visa and AbbVie

        The Zacks Analyst Blog Highlights: Apple, Visa and AbbVie

          Roche (RHHBY) Beats on Earnings in 2016, Misses on Sales

          Roche beat on earnings but missed on sales in 2016 due to decline in sales of Lucentis, Pegasys, Avastin and Tarceva.

            AbbVie (ABBV) HCV Regimen Gets Priority Review in Canada

            AbbVie Inc. (ABBV) announced that its New Drug Submission (NDS) for an investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) received priority review in Canada for treatment of HCV.

              Arpita Dutt headshot

              Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline

              2017 will be a year of significant R&D investment for AbbVie (ABBV) as well as several late-stage readouts which will give an insight into the company's long term growth prospects.

                Pfizer (PFE) Gets Positive CHMP Opinion for Arthritis Drug

                Pfizer Inc. (PFE) announced that Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for the company's marketing authorisation application (MAA) for its rheumatoid arthritis (RA) drug, Xeljanz.

                  Amgen Wins Favorable CHMP Opinion for Humira Biosimilar

                  Amgen (AMGN) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion on the company's marketing authorization application (MAA) for ABP 501.

                    AbbVie (ABBV) Q4 Earnings Meet Estimates, Revenues Lag

                    AbbVie (ABBV) reported earnings of $1.20 in the fourth-quarter of 2016, with revenues coming in at $6.80 billion.

                      AbbVie (ABBV) Reports In-Line Q4 Earnings, Revenues Miss

                      AbbVie (ABBV) reported earnings of $1.20 in the fourth-quarter of 2016, with revenues coming in at $6.80 billion.

                        Tracey Ryniec headshot

                        Friday's Best Earnings Charts

                        It's not easy to beat the estimate nearly every quarter.

                          Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft

                          Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, reported mixed fourth-quarter 2016.

                            AbbVie's HCV Regimen Okayed for Accelerated Assessment

                            AbbVie Inc. (ABBV) recently announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application for its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P).

                              Sunesis Offers Updates on SNS-062 and Qinprezo Programs

                              Sunesis (SNSS) provided updates on two of its lead programs: SNS-062, and Qinprezo (vosaroxin).

                                Can AbbVie (ABBV) Spring a Surprise This Earnings Season?

                                AbbVie Inc. (ABBV) is slated to release fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 27.

                                  Gilead (GILD) HCV Therapy Application Validated in Europe

                                  Gilead Sciences, Inc. (GILD) announced that its MAA for once-daily, single tablet regimen of Sovaldi, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for HCV treatment has been fully validated.

                                    What's in Store for Abbott Labs (ABT) This Earnings Season?

                                    Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.

                                      Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?

                                      Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report fourth-quarter and full year 2016 results on Jan 25.

                                        4 Drug Stocks Poised to Surprise this Earnings Season

                                        Market sentiment seems to be improving courtesy of raised outlooks, new product approvals and encouraging pipeline updates.

                                          Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?

                                          Celgene Corporation (CELG), which is set to report fourth-quarter 2016 results on Jan 26, reported a positive earnings surprise of 6.11% last quarter.

                                            Abbvie (ABBV) Imbruvica Approved in Lymphoma Indication

                                            AbbVie Inc. (ABBV) announced that the FDA has approved its blood cancer drug, Imbruvica, for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

                                              4 Best Marijuana Stocks to Play the Green Rush

                                              Not only is marijuana one of the fastest growing industries in the U.S., but it also received a major boost after the 2016 election. Find out which stocks you should play the green rush with.

                                                McKesson (MCK) Q3 Earnings: Stock Likely to Disappoint?

                                                McKesson Corporation (MCK), one of the largest healthcare services providers, is scheduled to report third-quarter fiscal 2017 results on Jan 25.

                                                  Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?

                                                  Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.